摘要
本文作者研究了上皮生长因子受体（ＥＧＦＲ）和Ｃ－ｅｒｂＢ－２癌基因蛋白在５０例甲状腺癌和６６例甲状腺良性疾患中的表达。５０例甲状腺癌中，ＥＧＦＲ阳性者２６例（５２％），Ｃ－ｅｒｂＢ－２阳性者２５例（５０％）。ＥＧＦＲ和ｃ－ｅｒｂＢ－２共同表达阳性者的淋巴结转移率（９２．８５％）明显高于两者共同表达阴性者（６１．５３％）（Ｐ＜０．０５）。ＥＧＦＲ阳性者ＡｇＮＯＲ数（２．５９±０．６４／核）也明显高于ＥＧＦＲ阴性者（１．３９±０．１８／核）（Ｐ＜０．００１）。ＥＧＦＲ与Ｃ－ｅｒｂＢ－２共同表达阳性，同时ＡｇＮＯＲ计数高的甲状腺癌具有较高的恶性度。因此，对这种病人要予以特别的治疗措施并抓紧随访工作。
The expression of EGFR and C-erbB-2
oncoproteins in 50 cases of thyroid carcinoma and 66 cases ofthyroid benign disease have
been studied. Among 50 cases of thyroid carcinoma, positive staining was found in
26cases(52%)for EGFR,25 cases(50%)for C-erbB-2。 The metastatic rate of lymph nodes in
EGFR(+),C-erbB-2(+)Group(92. 85%)was significantly higher than that of EGF(一),
C-erbB-2(一)group(6l. 53%)(P<0.05). The number of AgNORs in EGFR(+)group(2。 59±0.
64/nucleus)was also significantly higher than thatof EGFR(一)group(1. 39±0.18/nucleus)( P<0.
001).Thyroid carcinomas with expression of EGFR(+),C-erbB-2 (+)and simultaneously with high
number of AgNORs are more likely to have a higher malignancy。Therefore ,special
therapeutic measures and close follow-up are appropriate for these patients.
出处
《实用癌症杂志》
1995年第2期102-104,共3页
The Practical Journal of Cancer
